Current stock page

Stock Analysis

BridgeBio Pharma, Inc. (BBIO) Stock Analysis

BridgeBio Pharma, Inc. (BBIO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

BBIO Stock Analysis Summary

BridgeBio Pharma, Inc. (BBIO) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 69/100. Value is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

BBIO at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$78.30
AIQ Score64/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$15.35B
P/E Ratio (TTM)-25.76
Forward P/E—
EPS (Q3 FY2026)-$0.42
Revenue (Q3 FY2026)$353.17M
Dividend Yield (TTM)0.00%
Beta0.95
Volume1.15M
52-week range$62.50-$93.42
RSI 1464.96
50-Day SMA$69.98
200-Day SMA$72.69
Analyst Price Target$111.17
Next EarningsFeb 23, 2027
As of Nov 13, 2026 · Market close

BBIOBridgeBio Pharma, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$78.30+$0.13 (+0.17%)

Latest quote

  • Momentum
    69
  • Value
    55
  • Quality
    66
  • Risk resilience
    62
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

BBIO Stock Analysis Summary

BridgeBio Pharma, Inc. (BBIO) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 69/100. Value is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, BBIO has AIQ Score of 64/100 with Momentum base of 69/100 and fading Value at 55/100. Wait for component alignment before adding exposure.

Healthcare · 0.17% stock move · BBIO classified in Biotechnology.

Current Evidence

NeutralBBIO is in a neutral AIQ regime; Momentum is the strongest visible factor at 69/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is BBIO Bullish or Bearish Right Now?

BBIO currently has a neutral overall setup. Momentum is the strongest factor at 69/100, while Value is weakest at 55/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 66/100.
  • - Momentum is constructive at 69/100.
  • - Price is +11.89% above its 50-day SMA.
  • - Analyst target implies +41.98% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (36 vs 5).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

BBIO's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 5 neutral, and 5 sell votes. BBIO's 14-day RSI is 64.96, which places the stock in a constructive momentum range. BBIO's beta is 0.95, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in BBIO?

The largest recent change in BBIO is Momentum moving up by 5.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+5.0
Quality
+1.0
Risk
+0.0

What Would Change the BBIO Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

BBIO Decision Framework

Public evidence layers, setup checks, and risk context for BridgeBio Pharma, Inc..

BridgeBio Pharma, Inc. (BBIO) Stock Analysis

BridgeBio Pharma, Inc. has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 69/100. Beta is 0.95, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextBBIO is in a Neutral AIQ regime with score 64/100.
Signal ConflictThe primary conflict is that momentum leads at 69/100 while value lags at 55/100.
Factor EvidenceMomentum 69/100 · Value 55/100 · Quality 66/100 · Risk 62/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 69/100.

TimingPass

Momentum is 69/100 and RSI (14) is 65.0.

Regime fitWait

BBIO is in a Neutral regime at 64/100.

Risk controlWait

Risk factor is 62/100 with beta 0.95 and annual volatility 44.14%.

ConflictPass

Current conflict: momentum leads at 69/100 while value lags at 55/100.

AIQ Score
64/100
Price
$78.30
Beta
0.95
RSI (14)
65

BBIO Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

BBIO Fundamentals

BBIO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$353.17M
Net income
-$56.71M
Free cash flow
-$44.46M
View full BBIO fundamental analysis

BBIO Technical Analysis

BBIO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
64.96
Price vs SMA-50
+11.89%
View full BBIO technical analysis

BBIO Stock Catalysts

Track BBIO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 23, 2027
Analyst target
$111.17
News items
2
View BBIO earnings and stock catalysts

BBIO Dividend Analysis

BBIO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View BBIO dividend history and analysis

BBIO Financial Data

BBIO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$353.17M
EPS
-$0.42
Periods
8
View BBIO financials

BBIO Risk Analysis

BBIO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.95
Risk score
62/100
1Y volatility
44.14%
View BBIO risk analysis

BBIO Stock News

BBIO stock news, market tone, recent headlines, and catalyst context.

News items
2
Updated
Nov 15, 2026
Sentiment
—
Read BBIO stock news

BBIO vs Biotechnology Peers

Current peer cohort: BBIO · BCRX · BHVN · BLTE · CAI. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
BBIO
Current stock
64/10055/10069/10062/1000.5544.14%Current
BCRX
BioCryst Pharmaceuticals, Inc.
59/10086/10042/10055/1000.3648.06%BBIO vs BCRX
BHVN
Biohaven Ltd.
47/100—78/10035/100182.98%BBIO vs BHVN
BLTE
Belite Bio, Inc
74/100—71/10060/1000.953.71%BBIO vs BLTE
CAI
Caris Life Sciences, Inc.
70/10068/10085/10036/1000.2269.82%BBIO vs CAI
Pairwise Compare links: BCRX · BHVN · BLTE · CAIBBIO vs BCRXBBIO vs BHVNBBIO vs BLTEBBIO vs CAICompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a BBIO stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for BBIO: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-25.76
As of Nov 13, 2026
Revenue growth
192.60%
Gross margin
93.51%
Current debt / equity
-1.5
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$353.17M
Quarter net income
-$56.71M
Quarter free cash flow
-$44.46M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bullish
RSI 14
64.96
MACD
2.65

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
62/100
Beta
0.95
Annual volatility
44.14%
Max drawdown
-29.80%

BBIO Stock FAQ

What is BBIO stock price today?

BridgeBio Pharma, Inc.'s current stock price is $78.30. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is BBIO bullish or bearish right now?

BBIO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is BBIO's market cap?

BBIO's market cap is $15.35B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is BBIO's current P/E ratio?

BBIO's current P/E ratio is -25.76 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is BBIO's RSI?

BBIO's 14-day RSI is 64.96 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is BBIO above its 50-day and 200-day moving averages?

BBIO is 11.89% from its 50-day SMA and 7.71% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is BBIO's next earnings date?

BBIO's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does BBIO pay a dividend?

BBIO's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.